These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 30338649

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, Walls C, Wu WS, Dickson C, Liao R, Genovese MC.
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [Abstract] [Full Text] [Related]

  • 8. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
    Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N.
    J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
    [Abstract] [Full Text] [Related]

  • 9. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.
    Mori S, Fujiyama S.
    World J Gastroenterol; 2015 Sep 28; 21(36):10274-89. PubMed ID: 26420955
    [Abstract] [Full Text] [Related]

  • 10. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
    Tan J, Zhou J, Zhao P, Wei J.
    Clin Rheumatol; 2012 Aug 28; 31(8):1169-75. PubMed ID: 22544263
    [Abstract] [Full Text] [Related]

  • 11. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V, Viganò M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, Pellerito R, Rovera G, Caporali R, Todoerti M, Covelli M, Notarnicola A, Atzeni F, Sarzi-Puttini P.
    J Rheumatol; 2016 May 28; 43(5):869-74. PubMed ID: 26879359
    [Abstract] [Full Text] [Related]

  • 12. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Ogawa E, Furusyo N, Murata M, Toyoda K, Hayashi T, Ura K.
    Liver Int; 2018 Jan 28; 38(1):76-83. PubMed ID: 28618152
    [Abstract] [Full Text] [Related]

  • 13. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
    Talotta R, Atzeni F, Sarzi Puttini P.
    BMC Pharmacol Toxicol; 2016 Apr 21; 17():17. PubMed ID: 27098382
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
    Kuo MH, Tseng CW, Ko PH, Wang ST, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS.
    Liver Int; 2024 Feb 21; 44(2):497-507. PubMed ID: 38010984
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH, Bae SC, Song GG.
    Clin Exp Rheumatol; 2013 Feb 21; 31(1):118-21. PubMed ID: 23111095
    [Abstract] [Full Text] [Related]

  • 18. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
    Wang ST, Tseng CW, Hsu CW, Tung CH, Huang KY, Lu MC, Lai NS.
    Int J Rheum Dis; 2021 Nov 21; 24(11):1362-1369. PubMed ID: 34506078
    [Abstract] [Full Text] [Related]

  • 19. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH.
    J Med Virol; 2016 Jun 21; 88(6):1010-7. PubMed ID: 26531242
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.